We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ALCL

News List

Breaking News! The Second ADC Approved for Marketing in China PharmaSources/Xiaoyaowan
May 21, 2020
According to the NMPA website on May 13, the marketing application for Brentuximab Vedotin Injection filed by Takeda Pharmaceutical in China has been reviewed and approved, to become the second ADC approved for marketing in China.
Pfizer gets USFDA nod for XALKORI (crizotinib) to treat ALK-positive ALCL in children and young adults expresspharma
January 15, 2021
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people.
FDA grants priority review for Pfizer’s Xalkori in paediatric ALCL pharmaceutical-technology
September 27, 2020
Pfizer has secured priority review from the US Food and Drug Administration (FDA) for Xalkori (crizotinib) to treat relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) in children.